Oculis Holding AG (OCS) Restructuring Costs (2023)
Oculis Holding AG (OCS) posted quarterly Restructuring Costs of -$71325.6 for Q3 2023, up 97.33% quarter-over-quarter from -$2.7 million in Q2 2023.
Analysis
Oculis Holding AG (OCS) Restructuring Costs (2023) Analysis & Trends
Oculis Holding AG's Restructuring Costs history runs 1 years deep, the most recent figure standing at -$71325.6 for Q3 2023.
- In Q3 2023, Restructuring Costs changed N/A year-over-year to -$71325.6; the TTM figure through Dec 2023 stood at -$5.1 million (changed N/A YoY), while the FY2023 annual figure was -$5.1 million, down 2186.62% from the prior year.
- Restructuring Costs for Q3 2023 stood at -$71325.6, up from -$2.7 million in the prior quarter.
- The five-year high for Restructuring Costs was -$71325.6 in Q3 2023, with the low at -$2.7 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Oculis Holding AG | 634.75 Mn | 345.87 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2023 | -71,325.61 |
| Jun 30, 2023 | -2.67 Mn |
| Mar 31, 2023 | -2.31 Mn |